CORDIS
EU research results

CORDIS

English EN

Special Non-Invasive Advances in Foetal and Neonatal Evaluation Network

Project information

Grant agreement ID: 503243

  • Start date

    1 March 2004

  • End date

    28 February 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 13 140 000

  • EU contribution

    € 12 000 000

Coordinated by:

THE UNIVERSITY OF WARWICK

United Kingdom

Objective

The establishment of non-invasive markers for prenatal diagnosis is an important research goal. Current invasive procedures have a significant risk of induced abortion (1-2%) or maternal injury and considerable discomfort and psychological distress. Currently around 5% of pregnant women in the developed world undergo invasive prenatal diagnosis procedures, mainly due to an increased risk for foetal chromosome abnormalities . In populations with a high penetrance of an inherited genetic disorder, such as the hemoglobinopathies, cystic fibrosis or Tay Sachs syndrome, it may be advantageous to determine the genotype early in life (neonates), as this will alert individuals, who are found to be carriers of the risk of having an affected child. The transplacental passage of foetal cells into the maternal circulation is now well established, and a number of studies have been undertaken in order to isolate these rare foetal cells for prenatal diagnostic purposes. In spite of the technical problems imposed by the scarcity of these foetal cells (1/105 - 1/107), substantial progress has been made by individual research groups in Europe.

As these results are all based on small scale independent studies, there is now an urgent need to integrate these fragmented and diverse activities into a coherent strategy for non-invasive prenatal diagnosis. The recent discovery of relatively abundant quantities of cell free DNA in maternal plasma and serum has opened a new avenue for the prenatal diagnosis of the latter group of genetic disorders as well as the determination of the foetal RhD genotype in pregnancies at risk for HDN (haemolytic disease of the foetus and newborn). In addition elevations in the concentration of the new found molecular analyte may be indicative of pregnancies bearing an aneuploid foetus or those at risk for pregnancy related disorders such as preterm labour or preeclampsia. This opens the possibility for new screening tools.

Coordinator

THE UNIVERSITY OF WARWICK

Address

Gibbet Hill Road
Coventry

United Kingdom

Participants (48)

UNIVERSITY OF BASEL

Switzerland

UNIVERSITY OF THE WEST OF ENGLAND, BRISTOL

United Kingdom

OXFORD BROOKES UNIVERSITY

United Kingdom

KING'S COLLEGE LONDON

United Kingdom

UNIVERSITAT ROVIRA I VIRGILI

Spain

MEDIZINISCHE UNIVERSITAET GRAZ (MEDICAL UNIVERSITY GRAZ)

Austria

SANQUIN BLOOD SUPPLY FOUNDATION

Netherlands

CHARLES UNIVERSITY PRAGUE, 2ND MEDICAL FACULTY

Czechia

METASYSTEMS HARD UND SOFTWARE GMBH

Germany

IMSTAR SA

France

HELSINKI UNIVERSITY

Finland

ESTONIAN BIOCENTRE

Estonia

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

Italy

UNIVERSITY MEDICAL CENTER NIJMEGEN

Netherlands

AMERICAN HOSPITAL OF PARIS

France

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Greece

CHAIM SHEBA MEDICAL CENTER

Israel

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Spain

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

THE CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS

Cyprus

UNIVERSITY OF BRISTOL

United Kingdom

UNIVERSITY OF ZURICH

Switzerland

UNIVERSITA' DEGLI STUDI DI PERUGIA'

Italy

INSTITUT NATIONAL DE SANTE ET FECHERCHE MEDICALE

France

STATISTIK DR. M. BUSER

Switzerland

GENETIC INTEREST GROUP

United Kingdom

THE OPEN UNIVERSITY CENTRE FOR EDUCATION IN MEDICINE

United Kingdom

ZHONGSHAN MEDICAL COLLEGE, SUN YAT-SEN UNIVERSITY

China

NHS BLOOD AND TRANSPLANT

United Kingdom

LUND UNIVERSITY HOSPITAL BLOOD CENTRE

Sweden

UNIVERSITY COLLEGE LONDON

United Kingdom

LEON KOZMINSKI ACADEMY OF ENTREPRENEURSHIP AND MANAGEMENT

Poland

ECOLE PRATIQUE DES HAUTES ETUDES

France

CARL ZEISS MICROIMAGING GMBH

Germany

ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA DIPARTIMENTO DI MEDICINA INTERNA CARDIOANGIOLOGIA EPATOLOGIA

Italy

KAROLINSKA INSTITUTET

Sweden

MICROBIOLOGY RESEARCH CENTRE HOLLAND

Netherlands

THE RARE CHROMOSOME DISORDER SUPPORT GROUP

United Kingdom

STATENS SERUM INSTITUT

Denmark

GENERAL LAB S.A.

Spain

VU UNIVERSITY MEDICAL CENTER

Netherlands

WAYPOINT SYSTEMS LTD

United Kingdom

CNR-CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

India

UNIVERSITY OF COPENHAGEN

Denmark

UNIVERSITÀ DEGLI STUDI DI TRENTO

Italy

UNIVERSITÄTSMEDIZIN GÖTTINGEN - GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN - STIFTUNG ÖFFENTLICHEN RECHTS

Germany

Project information

Grant agreement ID: 503243

  • Start date

    1 March 2004

  • End date

    28 February 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 13 140 000

  • EU contribution

    € 12 000 000

Coordinated by:

THE UNIVERSITY OF WARWICK

United Kingdom